Inositol
17 benefits mapped to clinical evidence across supplements.
Dose per serving from products
6,110 products in our catalogue print how much Inositol a serving holds.
Most common: 25 mg to 50 mg, 17% of 6,110 products.
| Dose per serving | Products |
|---|---|
| 25 mcg or less | 297 |
| 25 mcg to 50 mcg | 412 |
| 50 mcg to 100 mcg | 67 |
| 100 mcg to 250 mcg | 16 |
| 250 mcg to 500 mcg | 23 |
| 500 mcg to 1 mg | 123 |
| 1 mg to 2.5 mg | 228 |
| 2.5 mg to 5 mg | 241 |
| 5 mg to 10 mg | 496 |
| 10 mg to 25 mg | 848 |
| 25 mg to 50 mg | 1,052 |
| 50 mg to 100 mg | 886 |
| 100 mg to 250 mg | 501 |
| 250 mg to 500 mg | 211 |
| 500 mg to 1 g | 283 |
| 1 g to 2.5 g | 372 |
| over 2.5 g | 54 |
Dose per serving from research
91 study groups in 78 studies say how much Inositol participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 2.5 g to 5 g, 46% of 91 study groups.
| Daily dose | Study groups |
|---|---|
| 250 mg or less | 4 |
| 250 mg to 500 mg | 3 |
| 500 mg to 1 g | 7 |
| 1 g to 2.5 g | 25 |
| 2.5 g to 5 g | 42 |
| 5 g to 10 g | 2 |
| 10 g to 25 g | 8 |
Commonly used together
44 of 87 study groups took Inositol with something else. Shown: what 3 or more different studies gave. The 10 most common of 12.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Folic Acid | 37 |
| Vitamin D | 6 |
| Zinc | 6 |
| Calcium | 5 |
| Iodine | 5 |
| Iron | 5 |
| Probiotics | 5 |
| Riboflavin | 5 |
| Vitamin B12 | 5 |
| Vitamin B6 | 5 |
Benefit Evidence
Research sources
Metabolism (46)
- Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS
PubMed ID: 24351072
RCT comparing myo‑ and D‑chiro‑inositol in PCOS showed metabolic parameter improvement, especially with myo‑inositol.
- Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study
PubMed ID: 23336594
12‑week myo‑inositol in PCOS improved insulin sensitivity (HOMA) and glucose‑insulin indices — clinical metabolic benefit.
- Effect of dietary myo-inositol supplementation in pregnancy on the incidence of maternal gestational diabetes mellitus and fetal outcomes: a randomized controlled trial
PubMed ID: 23327487
Randomized trial in high‑risk pregnant women: myo‑inositol markedly reduced gestational diabetes incidence — strong metabolic benefit.
- myo-Inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study
PubMed ID: 23340885
First‑trimester myo‑inositol halved relative risk of GDM and reduced fasting glycemia/macrosomia — robust metabolic outcome in pregnancy.
- Myo-inositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation
PubMed ID: 24488919
Pilot RCT in pregnancy showed improved glycemia and lipids with myo‑/D‑chiro‑inositol but product combined with folic acid and manganese.
- Chronic consumption of an inositol-enriched carob extract improves postprandial glycaemia and insulin sensitivity in healthy subjects: A randomized controlled trial
PubMed ID: 26051494
Randomized double‑blind trial in healthy adults: chronic inositol drink improved insulin sensitivity and lowered postprandial glucose (~14% reduction).
- Myo-inositol Supplementation for Prevention of Gestational Diabetes in Obese Pregnant Women: A Randomized Controlled Trial
PubMed ID: 26241420
Well‑powered RCT in obese pregnant women: myo‑inositol halved gestational diabetes incidence and improved HOMA‑IR, strong metabolic effect.
- Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial
PubMed ID: 26698911
Randomized trial in overweight pregnant women showing large reduction in GDM incidence with early myo‑inositol administration.
- Myo-inositol vs. D-chiro inositol in PCOS treatment
PubMed ID: 25670222
6‑month RCT in PCOS showed improved insulin resistance with myo‑ or D‑chiro‑inositol, supporting metabolic benefits in insulin‑resistant states.
- Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS)
PubMed ID: 27808588
RCT showing myo‑inositol produced metabolic improvements comparable to metformin in PCOS (insulin sensitivity, BMI).
- Myo-inositol and melatonin in the menopausal transition
PubMed ID: 27910708
Myo‑inositol in menopausal women reduced serum insulin over 6 months (human supplement trial showing metabolic effect).
- Effect of consumption of a carob pod inositol-enriched beverage on insulin sensitivity and inflammation in middle-aged prediabetic subjects
PubMed ID: 27713964
Randomized trial of a pinitol (inositol stereoisomer) drink improved insulin, HOMA‑IR and glycaemia (direct metabolic benefit).
- Effect of Non-Surgical Periodontal Therapy Along With Myo-Inositol on High-Sensitivity C-Reactive Protein and Insulin Resistance in Women With Polycystic Ovary Syndrome and Chronic Periodontitis: A Randomized Controlled Trial
PubMed ID: 28598285
Myo‑inositol (with periodontal therapy) improved HOMA and systemic inflammation in women with PCOS—supports metabolic benefit in PCOS context.
- Can trans resveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?
PubMed ID: 28703838
Myo/D‑chiro‑inositol + trans‑resveratrol improved fasting glucose and lipids vs inositols alone in pregnant overweight women.
- Metformin vs myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study
PubMed ID: 28092404
In obese PCOS, myo‑inositol improved insulin responses (though metformin had broader endocrine effects).
- Phytate Decreases Formation of Advanced Glycation End-Products in Patients with Type II Diabetes: Randomized Crossover Trial
PubMed ID: 29941991
Dietary IP6 (phytate) in T2DM reduced AGEs and modestly lowered HbA1c (small RCT).
- Effect of inositol stereoisomers at different dosages in gestational diabetes: an open-label, parallel, randomized controlled trial
PubMed ID: 29774465
In GDM women, myo‑inositol lowered HOMA‑IR, limited weight gain and reduced insulin requirement.
- Effects of a Carob-Pod-Derived Sweetener on Glucose Metabolism
PubMed ID: 29495516
Pinitol (inositol derivative) drink improved glucose in IGT and altered insulin/β‑cell related proteins (RCT).
- Comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome: a randomized controlled clinical trial
PubMed ID: 30608001
Myo‑inositol vs metformin in PCOS improved fasting glucose, insulin and HOMA‑IR and lowered TG—direct metabolic benefit.
- Impact of myoinositol with metformin and myoinositol alone in infertile PCOS women undergoing ovulation induction cycles - randomized controlled trial
PubMed ID: 32945218
Myo‑inositol alone delivered metabolic/improved pregnancy outcomes comparable to MI+metformin with fewer side effects.
- Myoinositol versus metformin pretreatment in GnRH-antagonist cycle for women with PCOS undergoing IVF: a double-blinded randomized controlled study
PubMed ID: 34590929
Myo‑inositol pre‑treatment in PCOS IVF improved metabolic markers (and fertility), supporting metabolic effects.
- The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial
PubMed ID: 34665453
Trial found myo‑inositol produced metabolic improvements comparable to metformin (BMI, body composition, glycemia).
- Myoinositol plus α-lactalbumin supplementation, insulin resistance and birth outcomes in women with gestational diabetes mellitus: a randomized, controlled study
PubMed ID: 33893377
Myo‑inositol+α‑lactalbumin in GDM improved insulin resistance and lowered insulin need — supports metabolic benefits though combination product complicates attribution.
- Efficacy of myoinositol in treatment of gestational diabetes mellitus in Asian Indian women: A pilot randomized clinical trial
PubMed ID: 33721623
Pilot RCT in GDM (myo‑inositol) improved glycemic control and reduced need for pharmacologic therapy — direct metabolic support evidence.
- The effect of myo-inositol supplementation on the prevention of gestational diabetes in overweight pregnant women: a randomized, double-blind, controlled trial
PubMed ID: 35686634
Double‑blind RCT in overweight pregnant women reduced GDM incidence with myo‑inositol — strong metabolic support signal.
- Daily phytate intake increases adiponectin levels among patients with diabetes type 2: a randomized crossover trial
PubMed ID: 36854678
InsP6 (phytate) crossover in T2DM increased adiponectin and modestly lowered HbA1c — related inositol derivative showing metabolic benefit.
- Effect of dietary myo-inositol supplementation on the insulin resistance and the prevention of gestational diabetes mellitus: an open-label, randomized controlled trial
PubMed ID: 39141124
Open‑label RCT found lower GDM rates and improved OGTT/HOMA‑IR with daily myo‑inositol — robust support for metabolic effects in pregnancy.
- Effectiveness of dual combination therapy of acarbose plus metformin and acarbose plus myo-inositol in ameliorating the metabolic and endocrinologic complications of polycystic ovary syndrome - A randomized controlled trial
PubMed ID: 38972164
PCOS RCT showed adding myo‑inositol improved insulin and lipid measures — supports metabolic benefits in PCOS.
- Effectiveness of a Food Supplement Based on Glucomannan, D-Chiro-Inositol, Cinnamomum zeylanicum Blume and Inulin in Patients with Metabolic Syndrome
PubMed ID: 38257142
Multi‑ingredient D‑chiro‑inositol product improved weight, insulin markers and lipids in metabolic syndrome, but attribution to DCI alone is uncertain.
- Comparative efficacy of combined myo-inositol and D-chiro inositol versus metformin across PCOS Phenotypes: enhancing ovarian function, ovulation, and stress response in a prospective clinical trial
PubMed ID: 39847053
Randomized 12‑week MI+DCI improved HOMA‑IR/insulin sensitivity in PCOS, comparable to metformin — direct metabolic benefit.
- Effect of Myo-Inositol Treatment on Serum Asprosin Levels of Pregnant Women: A Prospective Randomized Controlled Pilot Study
PubMed ID: 41497562
Randomized pilot: early pregnancy MI lowered asprosin and mid‑pregnancy fasting glucose vs folic acid — supports glycemic/metabolic effects.
- The effect of a preconception and antenatal nutritional supplement on children's BMI and weight gain over the first 2 years of life: findings from the NiPPeR randomised controlled trial
PubMed ID: 36866469
Preconception/pregnancy supplement including myo‑inositol reduced rapid infant weight gain and lowered risk of BMI>95th centile at age 2, indicating metabolic/weight effects in offspring.
- Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes - a randomized and open-label, placebo-controlled clinical trial
PubMed ID: 33238798
Myo‑inositol in pregnant overweight women reduced gestational diabetes incidence and limited adverse body‑water changes—strong metabolic effect.
- Pinitol consumption improves liver health status by reducing oxidative stress and fatty acid accumulation in subjects with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial
PubMed ID: 31030165
Pinitol RCT in NAFLD reduced liver fat, liver enzymes and postprandial triglycerides (supports metabolic/lipid benefits for an inositol-related compound).
- Clinical effectiveness of α-lipoic acid, myo-inositol and propolis supplementation on metabolic profiles and liver function in obese patients with NAFLD: A randomized controlled clinical trial
PubMed ID: 36963888
8‑week RCT in obese NAFLD patients found myo‑inositol with dietary advice improved glycemic and some lipid measures and reduced steatosis (direct metabolic signal).
- Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome
PubMed ID: 10219066
D-chiro-inositol randomized trial in PCOS markedly improved insulin AUC and metabolic markers.
- Effects of pinitol isolated from soybeans on glycaemic control and cardiovascular risk factors in Korean patients with type II diabetes mellitus: a randomized controlled study
PubMed ID: 15536472
Soybean‑derived pinitol (methylated inositol) RCT improved fasting glucose, HbA1c and LDL in T2D — strong metabolic signal.
- Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial
PubMed ID: 19499845
Myo-inositol RCT in women with PCOS produced large improvements in insulin AUC (−35%), ISI (+80%) and triglycerides (−51%) — strong metabolic benefit.
- Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women
PubMed ID: 20222840
Myo-inositol restored ovulation vs metformin and increased pregnancy rate; while fertility endpoints, this trial implies improved metabolic/insulin-mediated PCOS physiology.
- Effects of pinitol on glycemic control, insulin resistance and adipocytokine levels in patients with type 2 diabetes mellitus
PubMed ID: 22179130
Pinitol (a cyclitol related to inositol) RCT showed improved glycemic control and insulin resistance in T2DM—supports metabolic effect across related cyclitols.
- One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome
PubMed ID: 22192068
Randomized 12‑month myo‑inositol trial in postmenopausal metabolic syndrome: large, clinically meaningful improvements in glucose, HOMA‑IR, TG and HDL.
- Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study
PubMed ID: 20811299
Same/population‑consistent randomized data showing major improvements in insulin resistance, BP and lipids with myo‑inositol + diet.
- The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome
PubMed ID: 21417594
PCOS study: adding myo‑inositol to OCP yielded superior improvements in insulin resistance and lipids vs OCP alone.
- The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes
PubMed ID: 21414183
Randomized gestational diabetes trial: myo‑inositol substantially reduced HOMA‑IR and increased adiponectin.
- The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone
PubMed ID: 22774396
Overweight PCOS study: MI and MI+DCI improved metabolic syndrome/insulin resistance parameters (combination acted faster).
- Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial
PubMed ID: 23981814
Large RCT in metabolic‑syndrome postmenopausal women: inositol+α‑lipoic acid produced large, clinically meaningful reductions in HOMA‑IR, insulin and triglycerides.
Blood sugar (42)
- Effect of consumption of a carob pod inositol-enriched beverage on insulin sensitivity and inflammation in middle-aged prediabetic subjects
PubMed ID: 27713964
Pinitol beverage RCT improved insulin, HOMA‑IR and postprandial/nocturnal glucose (direct glycaemic improvements).
- Myo-inositol and melatonin in the menopausal transition
PubMed ID: 27910708
Myo‑inositol lowered serum insulin over 6 months in menopausal women (human supplement trial showing improved glycaemic marker).
- Myo-inositol vs. D-chiro inositol in PCOS treatment
PubMed ID: 25670222
PCOS RCT demonstrated improved insulin resistance with myo‑ or D‑chiro‑inositol, supporting glycemic benefits in insulin‑resistant populations.
- Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial
PubMed ID: 26698911
RCT in overweight pregnant women found a large reduction in GDM incidence with early myo‑inositol supplementation.
- Clinical effectiveness of α-lipoic acid, myo-inositol and propolis supplementation on metabolic profiles and liver function in obese patients with NAFLD: A randomized controlled clinical trial
PubMed ID: 36963888
Myo‑inositol arm showed the greatest improvement in glycemic indices in an RCT of obese NAFLD patients (direct signal for glycemic benefit).
- Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome
PubMed ID: 10219066
D-chiro-inositol trial produced a large (~62%) reduction in insulin AUC — strong glycemic/metabolic benefit in PCOS cohort.
- Effects of pinitol isolated from soybeans on glycaemic control and cardiovascular risk factors in Korean patients with type II diabetes mellitus: a randomized controlled study
PubMed ID: 15536472
Soybean‑derived pinitol RCT in T2D showed significant decreases in fasting glucose and HbA1c.
- Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial
PubMed ID: 19499845
Myo-inositol RCT in PCOS showed a 35% reduction in insulin AUC and an 80% increase in ISI composite — strong evidence of improved glycemic/insulin metrics.
- Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women
PubMed ID: 20222840
Myo-inositol restored ovulation vs metformin in PCOS; improvements likely mediated by insulin-sensitizing effects though the trial focused on ovulation/pregnancy endpoints.
- Effects of pinitol on glycemic control, insulin resistance and adipocytokine levels in patients with type 2 diabetes mellitus
PubMed ID: 22179130
Pinitol RCT in T2DM: significant reductions in HbA1c, fasting glucose and HOMA‑IR—supports glycemic effect in related cyclitols.
- One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome
PubMed ID: 22192068
Myo‑inositol RCT in postmenopausal metabolic syndrome: large improvements in HOMA‑IR, glucose and insulin vs placebo.
- Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study
PubMed ID: 20811299
Same/population‑consistent randomized data reporting large reductions in HOMA‑IR and glycemia with myo‑inositol + diet.
- The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome
PubMed ID: 21417594
In PCOS, adding myo‑inositol to OCP produced significant reductions in fasting insulin and HOMA, supporting improved glycemic indices.
- The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes
PubMed ID: 21414183
Randomized trial in gestational diabetes: myo‑inositol substantially reduced HOMA‑IR and fasting glucose/insulin markers.
- Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial
PubMed ID: 23981814
Large RCT: inositol+α‑lipoic acid produced major reductions in HOMA‑IR and fasting insulin over 6 months — strong glycemic benefit.
- Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS
PubMed ID: 24351072
MI vs DCI in PCOS improved metabolic profile (HOMA) — evidence of improved glycemic control.
- Effect of dietary myo-inositol supplementation in pregnancy on the incidence of maternal gestational diabetes mellitus and fetal outcomes: a randomized controlled trial
PubMed ID: 23327487
Randomized prevention trial: myo‑inositol markedly reduced incidence of gestational diabetes (~87% relative reduction) — clear blood‑sugar benefit.
- A single acute dose of pinitol from a naturally-occurring food ingredient decreases hyperglycaemia and circulating insulin levels in healthy subjects
PubMed ID: 23790912
High single oral dose of pinitol (a methyl‑inositol) acutely reduced glucose and insulin responses — short‑term glycemic effect.
- myo-Inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study
PubMed ID: 23340885
First‑trimester myo‑inositol halved relative risk of GDM and lowered fasting OGTT glycemia — strong glucose control evidence in pregnancy.
- Myo-inositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation
PubMed ID: 24488919
Second‑trimester pilot RCT with combined myo‑/D‑chiro‑inositol improved glycemia but was a multi‑nutrient product, limiting attribution.
- Chronic consumption of an inositol-enriched carob extract improves postprandial glycaemia and insulin sensitivity in healthy subjects: A randomized controlled trial
PubMed ID: 26051494
12‑week randomized trial in healthy volunteers showed improved insulin sensitivity and ~14% lower postprandial glucose with an inositol‑enriched drink.
- Myo-inositol Supplementation for Prevention of Gestational Diabetes in Obese Pregnant Women: A Randomized Controlled Trial
PubMed ID: 26241420
Robust RCT in obese pregnant women: myo‑inositol significantly reduced gestational diabetes incidence and improved HOMA‑IR—strong evidence for glycemic control.
- Effect of inositol stereoisomers at different dosages in gestational diabetes: an open-label, parallel, randomized controlled trial
PubMed ID: 29774465
In GDM, myo‑inositol lowered HOMA‑IR and reduced insulin needs (randomized evidence).
- Phytate Decreases Formation of Advanced Glycation End-Products in Patients with Type II Diabetes: Randomized Crossover Trial
PubMed ID: 29941991
Dietary IP6 lowered AGEs and modestly reduced HbA1c in T2DM (small randomized crossover).
- Metformin vs myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study
PubMed ID: 28092404
Myo‑inositol improved insulin responses in obese PCOS (crossover RCT), supporting glycaemic benefit.
- Can trans resveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients?
PubMed ID: 28703838
Combination DCI/MI + trans‑resveratrol improved fasting glucose vs inositols alone in overweight pregnant subjects.
- Daily phytate intake increases adiponectin levels among patients with diabetes type 2: a randomized crossover trial
PubMed ID: 36854678
Phytate (InsP6) crossover in T2DM increased adiponectin and modestly lowered HbA1c — related inositol derivative evidence for glycemic improvement.
- Efficacy of myoinositol in treatment of gestational diabetes mellitus in Asian Indian women: A pilot randomized clinical trial
PubMed ID: 33721623
Pilot RCT in Asian‑Indian women with GDM showed improved glycemic control and reduced need for medication with myo‑inositol — solid supportive evidence.
- Myoinositol plus α-lactalbumin supplementation, insulin resistance and birth outcomes in women with gestational diabetes mellitus: a randomized, controlled study
PubMed ID: 33893377
Myo‑inositol+α‑lactalbumin in GDM improved insulin resistance and reduced insulin requirement — strong signal for glycemic control (combination product).
- The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial
PubMed ID: 34665453
Myo‑inositol produced glycemic improvements similar to metformin across 6 months in PCOS patients.
- Myoinositol versus metformin pretreatment in GnRH-antagonist cycle for women with PCOS undergoing IVF: a double-blinded randomized controlled study
PubMed ID: 34590929
Myo‑inositol improved fasting insulin and HOMA in PCOS IVF patients, supporting glycemic control effects.
- Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes - a randomized and open-label, placebo-controlled clinical trial
PubMed ID: 33238798
Myo‑inositol supplementation in pregnant overweight women significantly reduced gestational diabetes incidence—robust glycemic prevention outcome.
- Impact of myoinositol with metformin and myoinositol alone in infertile PCOS women undergoing ovulation induction cycles - randomized controlled trial
PubMed ID: 32945218
Myo‑inositol alone produced similar metabolic outcomes to MI+metformin in infertile PCOS (RCT data).
- Comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome: a randomized controlled clinical trial
PubMed ID: 30608001
Myo‑inositol improved fasting plasma glucose, insulin and HOMA‑IR vs metformin over 12 weeks in PCOS—direct glycemic benefit.
- Effects of a Carob-Pod-Derived Sweetener on Glucose Metabolism
PubMed ID: 29495516
Pinitol (inositol derivative) drink improved fasting/postprandial glucose in IGT (randomized human data + mechanism).
- Effect of Non-Surgical Periodontal Therapy Along With Myo-Inositol on High-Sensitivity C-Reactive Protein and Insulin Resistance in Women With Polycystic Ovary Syndrome and Chronic Periodontitis: A Randomized Controlled Trial
PubMed ID: 28598285
Myo‑inositol (with periodontal therapy) improved HOMA in women with PCOS—supports improved insulin resistance/glycaemic control in PCOS context.
- Effect of Myo-Inositol Treatment on Serum Asprosin Levels of Pregnant Women: A Prospective Randomized Controlled Pilot Study
PubMed ID: 41497562
Early pregnancy MI reduced asprosin and produced lower fasting glucose at mid‑pregnancy vs folic acid in a small RCT — supports glycemic control.
- Comparative efficacy of combined myo-inositol and D-chiro inositol versus metformin across PCOS Phenotypes: enhancing ovarian function, ovulation, and stress response in a prospective clinical trial
PubMed ID: 39847053
MI+DCI improved insulin sensitivity (HOMA‑IR) significantly in a randomized trial in PCOS — direct glycemic benefit.
- Effectiveness of a Food Supplement Based on Glucomannan, D-Chiro-Inositol, Cinnamomum zeylanicum Blume and Inulin in Patients with Metabolic Syndrome
PubMed ID: 38257142
D‑chiro‑inositol containing multi‑ingredient supplement improved insulin, HOMA‑IR and weight in metabolic syndrome, though attribution to DCI alone is uncertain.
- Effectiveness of dual combination therapy of acarbose plus metformin and acarbose plus myo-inositol in ameliorating the metabolic and endocrinologic complications of polycystic ovary syndrome - A randomized controlled trial
PubMed ID: 38972164
PCOS RCT reported further decreases in fasting insulin and HOMA‑IR when myo‑inositol was included — supports glucose regulation in PCOS.
- Effect of dietary myo-inositol supplementation on the insulin resistance and the prevention of gestational diabetes mellitus: an open-label, randomized controlled trial
PubMed ID: 39141124
Open‑label RCT reported substantially lower GDM incidence and improved OGTT/HOMA‑IR with daily myo‑inositol — strong direct evidence of glycemic benefit in pregnancy.
- The effect of myo-inositol supplementation on the prevention of gestational diabetes in overweight pregnant women: a randomized, double-blind, controlled trial
PubMed ID: 35686634
Double‑blind RCT in overweight pregnant women found a large absolute reduction in GDM incidence with low‑dose myo‑inositol — high confidence for glycemic prevention.
Hormone balance (32)
- Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving in vitro fertilization of patients with polycystic ovarian syndrome
PubMed ID: 26507336
Large IVF study in PCOS patients (with melatonin) showed better oocyte/embryo outcomes suggesting improved ovarian function/ovulation quality.
- Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome
PubMed ID: 10219066
D-chiro-inositol trial showed marked reduction in free testosterone and restored ovulation in PCOS — strong hormonal effects.
- Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial
PubMed ID: 15206484
Inositol increased ovulation frequency in women with oligomenorrhea/PCOS in a large randomized trial.
- Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS
PubMed ID: 18074942
Randomized double‑blind RCT: myo‑inositol significantly increased ovulation frequency in women with PCOS — strong direct evidence.
- Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial
PubMed ID: 19499845
Randomized double-blind PCOS trial showed very large reductions in total testosterone (−65%) and improvements in insulin sensitivity — strong direct evidence for hormonal effects.
- Effect of the treatment with myo-inositol plus folic acid plus melatonin in comparison with a treatment with myo-inositol plus folic acid on oocyte quality and pregnancy outcome in IVF cycles. A prospective, clinical trial
PubMed ID: 20712264
IVF trial (both arms received myo-inositol) showed improved oocyte maturity when melatonin was added; supports role of myo-inositol in reproductive endocrinology though confounded by melatonin.
- Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women
PubMed ID: 20222840
Direct RCT evidence: myo-inositol restored ovulation in 65% of women with PCOS vs 50% with metformin — very strong, specific evidence for improved ovulation.
- Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial
PubMed ID: 21608442
ICSI RCT in PCOS: myo‑inositol increased mature oocytes and reduced immature oocytes—strong evidence of better oocyte maturation/ovulation quality.
- The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome
PubMed ID: 21417594
In PCOS patients myo‑inositol added to OCP produced greater reductions in insulin resistance and androgens and improved hirsutism score—direct hormonal effects.
- The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone
PubMed ID: 22774396
MI and MI+DCI improved ovarian/hormonal measures in overweight PCOS women; combination had faster effects.
- Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS
PubMed ID: 24351072
Head‑to‑head RCT in PCOS: myo‑ vs D‑chiro‑inositol showed both improved ovarian function with differential effects on androgens and metabolism.
- Inositol: effects on oocyte quality in patients undergoing ICSI. An open study
PubMed ID: 24302192
In ART patients, inositol improved oocyte quality and embryo transfer outcomes — supports improved oocyte maturation/ovulation relevance.
- Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study
PubMed ID: 23336594
Myo‑inositol reduced LH, PRL, testosterone and improved insulin in PCOS — demonstrated hormonal normalization.
- Myo-inositol vs. D-chiro inositol in PCOS treatment
PubMed ID: 25670222
RCT in PCOS showed improvements in endocrine parameters and menstrual regularity with myo‑ or D‑chiro‑inositol, supporting hormonal modulation.
- Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS)
PubMed ID: 27808588
Myo‑inositol produced endocrine/menstrual improvements comparable to metformin in PCOS, consistent with hormone‑balancing activity.
- Myo-inositol and melatonin in the menopausal transition
PubMed ID: 27910708
Myo‑inositol (alone/with melatonin) altered TSH in menopausal women (myo‑Ins alone lowered TSH), indicating a hormonal effect on thyroid markers.
- Myo-inositol plus selenium supplementation restores euthyroid state in Hashimoto's patients with subclinical hypothyroidism
PubMed ID: 28724185
Myo‑inositol + selenium in Hashimoto’s patients significantly reduced TSH and thyroid autoantibodies and increased free T4—strong clinical evidence for thyroid/hormonal effects (combination therapy).
- Comparison of myo-inositol and metformin on clinical, metabolic and genetic parameters in polycystic ovary syndrome: A randomized controlled clinical trial
PubMed ID: 28485095
Myo‑inositol in PCOS reduced total testosterone and hirsutism scores vs metformin, directly indicating improved androgen/hormone balance.
- Myo-inositol administration positively effects ovulation induction and intrauterine insemination in patients with polycystic ovary syndrome: a prospective, controlled, randomized trial
PubMed ID: 28277112
Myo‑inositol increased clinical pregnancy rates during ovulation induction and reduced stimulation requirements (supports ovulatory function).
- The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios
PubMed ID: 31298405
40:1 MI:DCI ratio best restored ovulation compared with other ratios in PCOS (randomized clinical comparison).
- Comparison of metformin plus myoinositol vs metformin alone in PCOS women undergoing ovulation induction cycles: randomized controlled trial
PubMed ID: 30614289
Myo‑inositol added to metformin improved menstrual outcomes and increased live births—consistent with better ovulation.
- The myo-inositol effect on the oocyte quality and fertilization rate among women with polycystic ovary syndrome undergoing assisted reproductive technology cycles: a randomized clinical trial
PubMed ID: 30919036
Pre‑treatment with myo‑inositol improved MII oocyte yield and fertilization rates in IVF patients (indicative of better ovulation/oocyte quality).
- The effectiveness of inositol and metformin on infertile polycystic ovary syndrome women with resistant to letrozole
PubMed ID: 30847561
Pre‑treatment improved ovarian function (ovulation) in letrozole‑resistant PCOS, notably in normal‑BMI subgroup.
- Impact of myoinositol with metformin and myoinositol alone in infertile PCOS women undergoing ovulation induction cycles - randomized controlled trial
PubMed ID: 32945218
Myo‑inositol alone achieved comparable reproductive outcomes to MI+metformin, implying an ovulatory benefit with good tolerability.
- Efficacy of myo-inositol and d-chiro-inositol combination on menstrual cycle regulation and improving insulin resistance in young women with polycystic ovary syndrome: A randomized open-label study
PubMed ID: 34624138
MI+DCI improved menstrual cycle parameters and insulin resistance with resumption of spontaneous menses in most treated PCOS women, indicating improved ovulatory function.
- The effect of Myo-inositol on fertility rates in poor ovarian responder in women undergoing assisted reproductive technique: a randomized clinical trial
PubMed ID: 33892722
Myo‑inositol pre‑treatment improved ovarian sensitivity and fertilization in poor ovarian responders — suggests improved ovarian function/ovulation quality.
- Treatment with combined resveratrol and myoinositol ameliorates endocrine, metabolic alterations and perceived stress response in women with PCOS: a double-blind randomized clinical trial
PubMed ID: 36169918
Resveratrol+myo‑inositol improved androgens and adiponectin in obese PCOS women — suggests hormone‑modulating effects though combined therapy complicates attribution.
- Effectiveness of dual combination therapy of acarbose plus metformin and acarbose plus myo-inositol in ameliorating the metabolic and endocrinologic complications of polycystic ovary syndrome - A randomized controlled trial
PubMed ID: 38972164
Addition of myo‑inositol in PCOS trial helped correct reproductive hormone abnormalities (e.g., testosterone, SHBG changes) — direct hormonal effects.
- Improvement in biochemical manifestations of the serum and follicular fluid and ICSI outcomes in PCOS patients with myo-inositol administration: prospective randomized research
PubMed ID: 39718613
Myo‑inositol before ICSI in PCOS decreased LH and total testosterone and reduced oxidative stress — direct hormonal improvements.
- Comparative efficacy of combined myo-inositol and D-chiro inositol versus metformin across PCOS Phenotypes: enhancing ovarian function, ovulation, and stress response in a prospective clinical trial
PubMed ID: 39847053
MI+DCI increased menstrual regularity in PCOS, which commonly correlates with improved ovulatory patterns — plausible indirect support.
- The ameliorative effect of myo-inositol on apoptosis-related genes expression in cumulus cells of women with polycystic ovary syndrome undergoing ICSI and its relationship with the quality of oocyte and embryo
PubMed ID: 40019528
MI altered cumulus cell apoptosis gene expression correlated with better embryo quality; mechanistic reproductive/hormonal effects in PCOS context.
- Exercise combined with lysine-inositol vitamin B12 promotes height growth in children with idiopathic short stature
PubMed ID: 37245296
Exercise plus lysine‑inositol‑B12 increased GH/GHRH/IGF‑1/IGFBP‑3 in children—direct hormonal changes observed, though intervention was multi‑component.
Fertility (27)
- Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial
PubMed ID: 15206484
Inositol significantly increased ovulation frequency in women with oligomenorrhea/PCOS — direct fertility‑relevant outcome.
- Myoinositol/folic acid combination for the treatment of erectile dysfunction in type 2 diabetes men: a double-blind, randomized, placebo-controlled study
PubMed ID: 17121317
Myo‑inositol+folic acid improved erectile function in diabetic men — may aid male fertility/sexual function though fertility per se was not measured.
- Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS
PubMed ID: 18074942
Improved ovulation rates with myo‑inositol suggest potential fertility benefit though pregnancy outcomes were not primary endpoints.
- Effect of the treatment with myo-inositol plus folic acid plus melatonin in comparison with a treatment with myo-inositol plus folic acid on oocyte quality and pregnancy outcome in IVF cycles. A prospective, clinical trial
PubMed ID: 20712264
IVF trial (both groups on myo-inositol) showed improved oocyte maturity and more top-quality embryos when melatonin was added — supports a positive role for myo-inositol in assisted reproduction (confounded).
- Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women
PubMed ID: 20222840
Myo-inositol produced higher pregnancy rates than metformin in PCOS (48.4% vs 36.6%) and restored ovulation — strong fertility-relevant evidence.
- Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial
PubMed ID: 21608442
Randomized trial in PCOS patients undergoing ICSI: myo‑inositol increased mature oocytes, top‑quality embryos and pregnancies vs D‑chiro‑inositol—strong RCT evidence for fertility benefit.
- The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone
PubMed ID: 22774396
Combination MI+DCI in overweight PCOS improved ovarian measures faster than MI alone, supporting fertility‑related outcomes.
- Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS
PubMed ID: 24351072
MI and DCI improved ovarian function in PCOS; different isoforms had complementary effects relevant to fertility.
- Inositol: effects on oocyte quality in patients undergoing ICSI. An open study
PubMed ID: 24302192
Large randomized study in ICSI patients: adding inositol to folic acid improved oocyte/embryo quality and clinical pregnancy rates — robust fertility benefit.
- Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study
PubMed ID: 23336594
Myo‑inositol improved hormonal milieu and restored menses in PCOS — clinical improvements that can increase fertility potential.
- Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving in vitro fertilization of patients with polycystic ovarian syndrome
PubMed ID: 26507336
Large randomized trial in PCOS women undergoing IVF reported improved oocyte/embryo quality and higher pregnancy/implantation rates with myo‑inositol (combined with melatonin).
- Improving fertilization rate in ICSI cycles by adding myoinositol to the semen preparation procedures: a prospective, bicentric, randomized trial on sibling oocytes
PubMed ID: 25601322
Prospective randomized trial in ICSI cycles: in‑vitro sperm treatment with myo‑inositol increased fertilization rates and number of high‑quality embryos.
- Myo-inositol administration positively effects ovulation induction and intrauterine insemination in patients with polycystic ovary syndrome: a prospective, controlled, randomized trial
PubMed ID: 28277112
Myo‑inositol added to ovulation induction raised clinical pregnancy rates and reduced gonadotropin dose/duration (prospective RCT).
- The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios
PubMed ID: 31298405
MI:DCI 40:1 ratio most effective at restoring ovulation and improving reproductive markers in PCOS (RCT comparison).
- Comparison of metformin plus myoinositol vs metformin alone in PCOS women undergoing ovulation induction cycles: randomized controlled trial
PubMed ID: 30614289
Large RCT: adding myo‑inositol to metformin nearly doubled live birth rate vs metformin alone (robust clinical outcome).
- The ameliorative effect of myo-inositol on apoptosis-related genes expression in cumulus cells of women with polycystic ovary syndrome undergoing ICSI and its relationship with the quality of oocyte and embryo
PubMed ID: 40019528
MI altered cumulus cell gene expression toward survival and these molecular changes correlated with better embryo quality in an RCT — strong mechanistic fertility support.
- Improvement in biochemical manifestations of the serum and follicular fluid and ICSI outcomes in PCOS patients with myo-inositol administration: prospective randomized research
PubMed ID: 39718613
Myo‑inositol before ICSI improved embryo quality and favourable hormonal/oxidative changes in PCOS — strong direct support for fertility‑related outcomes.
- The effect of Myo-inositol on fertility rates in poor ovarian responder in women undergoing assisted reproductive technique: a randomized clinical trial
PubMed ID: 33892722
Myo‑inositol pre‑treatment in poor ovarian responders increased fertilization rate and ovarian sensitivity and lowered gonadotropin use — supports fertility‑enhancing effect in IVF context.
- Myoinositol versus metformin pretreatment in GnRH-antagonist cycle for women with PCOS undergoing IVF: a double-blinded randomized controlled study
PubMed ID: 34590929
Double‑blind RCT in PCOS IVF patients: myo‑inositol pre‑treatment improved fertilization, embryo quality and clinical pregnancy rate vs metformin.
- A phytotherapic approach to reduce sperm DNA fragmentation in patients with male infertility
PubMed ID: 28058714
Randomized placebo‑controlled trial: phytotherapeutic tablet containing myo‑inositol improved sperm concentration, motility and reduced DNA fragmentation vs placebo—direct evidence supporting male fertility improvements.
- Effect of myo-inositol supplementation on ICSI outcomes among poor ovarian responder patients: A randomized controlled trial
PubMed ID: 32018040
Pre‑treatment with myo‑inositol in poor ovarian responders improved fertilization rate and Grade A embryo count though pregnancy rates unchanged.
- Positive effect of a new supplementation of vitamin D(3) with myo-inositol, folic acid and melatonin on IVF outcomes: a prospective randomized and controlled pilot study
PubMed ID: 32367738
Pilot study: adding vitamin D3 to a myo‑inositol regimen raised vitamin D and was associated with higher implantation rates (small pilot; multi‑agent).
- The effect of myo-inositol, vitamin D3 and melatonin on the oocyte quality and pregnancy in in vitro fertilization: a randomized prospective controlled trial
PubMed ID: 32894558
Myo‑inositol combined with melatonin and vitamin D3 increased clinical pregnancy rate and improved oocyte/blastocyst quality in women undergoing ICSI (multimodal regimen).
- Impact of myoinositol with metformin and myoinositol alone in infertile PCOS women undergoing ovulation induction cycles - randomized controlled trial
PubMed ID: 32945218
Myo‑inositol alone produced similar clinical pregnancy rates to MI+metformin with fewer side effects (RCT in PCOS infertility).
- Comparison of the effect of two combinations of myo-inositol and D-chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial
PubMed ID: 30880505
Randomized double‑blind trial: high‑dose DCI + myo‑inositol markedly increased pregnancy and live birth rates in PCOS women undergoing ICSI (large effect).
- The myo-inositol effect on the oocyte quality and fertilization rate among women with polycystic ovary syndrome undergoing assisted reproductive technology cycles: a randomized clinical trial
PubMed ID: 30919036
Pre‑treatment with myo‑inositol in IVF/ICSI improved MII oocyte rate, fertilization and embryo quality (randomized trial).
- Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome
PubMed ID: 10219066
D-chiro-inositol markedly increased ovulation rate in PCOS, a direct fertility-relevant outcome.
Menstrual comfort (15)
- Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study
PubMed ID: 23336594
Myo‑inositol restored menstrual cyclicity in all amenorrheic/oligomenorrheic PCOS subjects in the trial — strong clinical effect on cycle regularity.
- Comparative efficacy of combined myo-inositol and D-chiro inositol versus metformin across PCOS Phenotypes: enhancing ovarian function, ovulation, and stress response in a prospective clinical trial
PubMed ID: 39847053
Randomized 12‑week MI+DCI improved menstrual regularity in women with PCOS (p=0.002) — direct evidence.
- A randomized controlled trial comparing myoinositol with metformin versus metformin monotherapy in polycystic ovary syndrome
PubMed ID: 37265016
Randomized trial found adding myo‑inositol to metformin produced significant improvements in menstrual regularity and PCOS‑specific QoL.
- Treatment with combined resveratrol and myoinositol ameliorates endocrine, metabolic alterations and perceived stress response in women with PCOS: a double-blind randomized clinical trial
PubMed ID: 36169918
Resveratrol+myo‑inositol markedly increased menstrual regularity vs comparator (81.4% vs 18.2%) — strong clinical reproductive rhythm benefit though combined therapy.
- Efficacy of myo-inositol and d-chiro-inositol combination on menstrual cycle regulation and improving insulin resistance in young women with polycystic ovary syndrome: A randomized open-label study
PubMed ID: 34624138
MI+DCI markedly improved resumption of spontaneous menses and reduced cycle length in young PCOS women vs baseline (durable after treatment).
- Comparison of metformin plus myoinositol vs metformin alone in PCOS women undergoing ovulation induction cycles: randomized controlled trial
PubMed ID: 30614289
Metformin + myo‑inositol markedly improved menstrual‑cycle regularity vs metformin alone (RCT).
- The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios
PubMed ID: 31298405
40:1 MI:DCI ratio best restored ovulation and reproductive normalization in PCOS, implying cycle regularity benefits.
- Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS)
PubMed ID: 27808588
Myo‑inositol treatment normalized menstrual cycles in ~50% of PCOS patients, comparable to metformin.
- Myo-inositol vs. D-chiro inositol in PCOS treatment
PubMed ID: 25670222
6‑month RCT in PCOS showed significant improvements in menstrual regularity with myo‑ or D‑chiro‑inositol versus placebo.
- Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS
PubMed ID: 24351072
MI and DCI improved ovarian function/menstrual cyclicity in PCOS women (RCT), supporting more regular periods.
- The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone
PubMed ID: 22774396
Overweight PCOS women treated with MI or MI+DCI showed faster/better ovarian function recovery with combination therapy — supports cycle improvements.
- Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women
PubMed ID: 20222840
Myo-inositol restored ovulation in a randomized trial versus metformin (ovulation restored in 65% vs 50%) — strong direct evidence for menstrual/ovulatory regularization in PCOS.
- Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS
PubMed ID: 18074942
Myo‑inositol increased ovulation frequency in women with PCOS — supports more regular periods.
- Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial
PubMed ID: 15206484
Large RCT in women with oligomenorrhea/PCOS showed increased ovulation frequency (direct evidence of more regular cycles).
- Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome
PubMed ID: 10219066
D-chiro-inositol restored ovulation in many obese PCOS women — strong evidence for menstrual regularization.
Weight management (7)
- Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome
PubMed ID: 10219066
PCOS trial improved insulin and androgens; metabolic improvements can support weight management though weight change not primary endpoint.
- Effectiveness of a Food Supplement Based on Glucomannan, D-Chiro-Inositol, Cinnamomum zeylanicum Blume and Inulin in Patients with Metabolic Syndrome
PubMed ID: 38257142
Multi‑ingredient D‑chiro‑inositol product produced ~3.4 kg weight loss and BMI reduction over 16 weeks in metabolic syndrome; effect may partly reflect DCI but product was combined.
- Use of Metabolomic Profiling to Understand Variability in Adiposity Changes Following an Intentional Weight Loss Intervention in Older Adults
PubMed ID: 33086512
Baseline myo‑inositol/carbohydrate metabolite peak predicted greater visceral fat loss on a hypocaloric diet—associative evidence linking inositol biology to weight change.
- Impact of preconception and antenatal supplementation with myo-inositol, probiotics, and micronutrients on offspring BMI and weight gain over the first 2 years
PubMed ID: 38287349
Large preconception/pregnancy supplement including myo‑inositol reduced obesity prevalence and rapid weight gain in offspring at age 2 — strong child weight‑support signal (multi‑ingredient product).
- The effect of a preconception and antenatal nutritional supplement on children's BMI and weight gain over the first 2 years of life: findings from the NiPPeR randomised controlled trial
PubMed ID: 36866469
Preconception/pregnancy supplement including myo‑inositol significantly reduced rapid infant weight gain and halved risk of BMI>95th centile at age 2—strong evidence for weight‑related programming benefit.
- Treatment with combined resveratrol and myoinositol ameliorates endocrine, metabolic alterations and perceived stress response in women with PCOS: a double-blind randomized clinical trial
PubMed ID: 36169918
Resveratrol+myo‑inositol arm had greater weight/BMI reductions vs comparator — supports weight benefit in PCOS context though combined intervention.
- Effect of inositol stereoisomers at different dosages in gestational diabetes: an open-label, parallel, randomized controlled trial
PubMed ID: 29774465
Myo‑inositol in GDM reduced maternal weight gain vs control (reported outcome in RCT).
Acne (5)
- Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study
PubMed ID: 23336594
Myo‑inositol reduced testosterone and restored menses in PCOS — plausible indirect benefit for acne/hyperandrogenic skin symptoms.
- Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome
PubMed ID: 10219066
D-chiro-inositol reduced free testosterone substantially — plausible mechanism for reducing acne in hyperandrogenic women (no direct acne endpoint).
- Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial
PubMed ID: 19499845
Myo-inositol produced a large drop in total testosterone (−65%) in PCOS women; androgen reduction is mechanistically linked to decreased acne risk though acne was not measured directly.
- The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome
PubMed ID: 21417594
Myo‑inositol with OCP reduced androgens and hirsutism score; androgen lowering plausibly reduces acne though acne was not a primary endpoint.
- Myo-inositol vs. D-chiro inositol in PCOS treatment
PubMed ID: 25670222
PCOS RCT reported reductions in acne scores with myo‑ or D‑chiro‑inositol over 6 months.
Stress resilience (3)
- Controlled trials of inositol in psychiatry
PubMed ID: 9169302
Review documents benefits in panic, OCD and depression, supporting improved resilience to stress-related psychiatric symptoms.
- Comparative efficacy of combined myo-inositol and D-chiro inositol versus metformin across PCOS Phenotypes: enhancing ovarian function, ovulation, and stress response in a prospective clinical trial
PubMed ID: 39847053
MI+DCI significantly improved perceived stress scores (PSS) in PCOS vs baseline/comparator — supports improved stress resilience.
- Treatment with combined resveratrol and myoinositol ameliorates endocrine, metabolic alterations and perceived stress response in women with PCOS: a double-blind randomized clinical trial
PubMed ID: 36169918
Resveratrol+myo‑inositol produced marked improvements in perceived stress scores — indicates improved stress resilience though multi‑ingredient.
Skin health (3)
- D-chiro-inositol as a treatment in plaque psoriasis: A randomized placebo-controlled clinical trial
PubMed ID: 33188584
Topical D‑chiro‑inositol increased lesion hydration and improved elasticity in mild plaque psoriasis—objective skin benefit though disease‑specific.
- Myo-inositol vs. D-chiro inositol in PCOS treatment
PubMed ID: 25670222
6‑month RCT in PCOS reported improvements in acne and androgenic symptoms with myo‑ or D‑chiro‑inositol.
- Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome
PubMed ID: 10219066
D-chiro-inositol reduced testosterone in PCOS — androgen reduction can improve acne/skin; no direct acne endpoint but plausible.
Mood balance (3)
- High-frequency rTMS treatment increases left prefrontal myo-inositol in young patients with treatment-resistant depression
PubMed ID: 20600472
Depression responders showed increases in left prefrontal myo-inositol that correlated with clinical improvement — supports an association between brain inositol status and mood.
- Comparison of myo-inositol and metformin on mental health parameters and biomarkers of oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial
PubMed ID: 28980870
RCT in women with PCOS showed myo‑inositol improved depression and general mental‑health scores versus metformin (direct clinical evidence).
- Controlled trials of inositol in psychiatry
PubMed ID: 9169302
Review concludes multiple controlled trials show benefits for depression and related disorders.
Hair & Nails (2)
- The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome
PubMed ID: 21417594
Significant reduction in Ferriman–Gallwey (hirsutism) score with myo‑inositol + OCP vs OCP alone—direct evidence for reduced excess hair.
- Comparison of myo-inositol and metformin on clinical, metabolic and genetic parameters in polycystic ovary syndrome: A randomized controlled clinical trial
PubMed ID: 28485095
Myo‑inositol decreased hirsutism (modified Ferriman‑Gallwey score) in PCOS, indicating beneficial effects on undesired hair growth (clinical hair‑related outcome).
Energy & Fatigue (2)
- Efficacy and Safety of "URSA Complex" in Subjects with Physical Fatigue: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial
PubMed ID: 26830981
URSA Complex increased the proportion meeting a defined fatigue‑recovery threshold at 4 weeks (subjective energy/fatigue endpoint), though multiple ingredients confound attribution.
- A Prospective Study Evaluating the Effects of a Nutritional Supplement Intervention on Cognition, Mood States, and Mental Performance in Video Gamers
PubMed ID: 31581523
Study reported increased perceived vigor after an inositol‑containing supplement, suggesting acute energy/vigor benefit.
Liver support (2)
- Clinical effectiveness of α-lipoic acid, myo-inositol and propolis supplementation on metabolic profiles and liver function in obese patients with NAFLD: A randomized controlled clinical trial
PubMed ID: 36963888
Myo‑inositol arm in obese NAFLD trial had favorable steatosis outcomes and improvements in related biomarkers (supports liver benefit).
- Pinitol consumption improves liver health status by reducing oxidative stress and fatty acid accumulation in subjects with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial
PubMed ID: 31030165
Pinitol RCT in NAFLD showed significant reductions in liver fat, liver enzymes and oxidative stress vs placebo (direct liver benefit).
Stress & Anxiety (2)
- Controlled trials of inositol in psychiatry
PubMed ID: 9169302
Review reports benefits for panic and other serotonin-responsive anxiety disorders with inositol.
- Comparison of myo-inositol and metformin on mental health parameters and biomarkers of oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial
PubMed ID: 28980870
Myo‑inositol improved DASS (anxiety/depression/stress) scores vs metformin in PCOS patients (direct clinical signal for anxiety symptoms).
Nerve health (2)
- Clinical effects of acupuncture for diabetic peripheral neuropathy
PubMed ID: 20397454
Oral inositol used as control therapy in diabetic peripheral neuropathy RCT produced symptom improvement (~64% effective) — direct evidence of nerve symptom benefit.
- The Efficacy of Sodium Phytate as a Natural Chelating Agent in Reducing Elevated Calcium Levels in Nasal Mucus Among Individuals Experiencing Olfactory Dysfunction Following COVID-19: A Prospective Randomized Double-Controlled Clinical Trial
PubMed ID: 38105576
Topical sodium phytate improved post‑COVID olfaction (nerve/sensory recovery) in an RCT — relevant to peripheral sensory nerve function.
Focus & concentration (1)
- A Prospective Study Evaluating the Effects of a Nutritional Supplement Intervention on Cognition, Mood States, and Mental Performance in Video Gamers
PubMed ID: 31581523
Inositol‑enhanced arginine silicate improved several executive function measures (TMT, Stroop) acutely in gamers; product was multi‑ingredient.
Sleep quality (1)
- The impact of myo-inositol supplementation on sleep quality in pregnant women: a randomized, double-blind, placebo-controlled study
PubMed ID: 32933356
Randomized double‑blind trial in pregnant women showed myo‑inositol 2 g/day improved PSQI total and multiple component sleep scores.
Similar by evidence
Supplements the same benefits carry qualifying findings for — a fact about the evidence graph, not a recommendation to swap.
Products with Inositol
Search all8470 products whose verified label declares Inositol — not every bottle that mentions it in a title.
Being studied right now
Recruiting clinical trials registered on ClinicalTrials.gov. A trial in progress has no result yet — this is what the field is asking, not what it found.